SCHEMBL2347477

SCHEMBL2347477

CCCc1ccc(Oc2cccc(CO)c2)cc1

nearest known ligand 0.53

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
LTA4H P09960 1/20 0.53
FDFT1 P37268 1/20 0.50
TSHR P16473 1/20 0.49
HSD17B10 Q99714 1/20 0.49
FFAR1 O14842 6/20 0.48
FFAR4 Q5NUL3 2/20 0.48
CETP P11597 1/20 0.47
KDM4E B2RXH2 1/20 0.46
ALDH1A1 P00352 1/20 0.46
HTT P42858 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
TTR P02766 1/20 0.45
GNA15 P30679 1/20 0.43
PTGER3 P43115 1/20 0.43
TDP1 Q9NUW8 1/20 0.43
P2RX3 P56373 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25381878 0.90 FDFT1 (0.57) FDFT1TSHRHSD17B10FFAR1FFAR4
SCHEMBL921397 0.84 ST14 (0.55) FDFT1TSHRHSD17B10FFAR1FFAR4
SCHEMBL10106203 0.83 FDFT1 (0.58) FDFT1CETP
SCHEMBL26218121 0.82 TAAR1 (0.50) FDFT1TSHRHSD17B10KDM4EALDH1A1
SCHEMBL6061333 0.82 F2 (0.51) FDFT1HSD17B10FFAR1FFAR4HTT
SCHEMBL6061334 0.82 LTA4H (0.50) LTA4HFDFT1TSHRHSD17B10FFAR1
SCHEMBL1746839 0.81 FFAR1 (0.53) LTA4HTSHRHSD17B10FFAR1FFAR4
SCHEMBL1681007 0.81 SMN1; SMN2 (0.60) LTA4HKDM4EALDH1A1HTTSMN1; SMN2
SCHEMBL1696397 0.81 KDM4E (0.55) LTA4HFDFT1TSHRHSD17B10FFAR1
SCHEMBL358425 0.81 LTA4H (0.67) LTA4HTSHRHSD17B10FFAR1FFAR4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8008525-B2 For the 14273 peroxisome proliferator activated receptor; antidiabetic agents, hyperlipidemia, obesity or anorexia; receptor binding assay; drug screening kits TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-08-30 US disclosed
US-8008525-B2 For the 14273 peroxisome proliferator activated receptor; antidiabetic agents, hyperlipidemia, obesity or anorexia; receptor binding assay; drug screening kits TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-08-30 US disclosed
US-8008525-B2 For the 14273 peroxisome proliferator activated receptor; antidiabetic agents, hyperlipidemia, obesity or anorexia; receptor binding assay; drug screening kits TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-08-30 US disclosed
US-20080167378-A1 Receptor Function Regulation Agent TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-07-10 US disclosed
US-20080167378-A1 Receptor Function Regulation Agent TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-07-10 US disclosed
US-20080167378-A1 Receptor Function Regulation Agent TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-07-10 US disclosed
EP-1688138-A1 RECEPTOR FUNCTION REGULATING AGENT Takeda Pharmaceutical Company Limited (JP) 2006-08-09 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080167378-A1 Receptor Function Regulation Agent GPR119, INSR, GPR88 LTA4H 1418/4885FDFT1 3463/4885TSHR 41/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.